{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T22:05:47Z","timestamp":1779919547734,"version":"3.53.1"},"reference-count":5,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.eururo.2026.02.002","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T12:28:57Z","timestamp":1771849737000},"page":"554-555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Re: Active Monitoring, Surgery, and Radiotherapy for Cribriform-positive and Cribriform-negative Prostate Cancer: A Secondary Analysis of the PROTECT Randomized Clinical Trial"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9198-9445","authenticated-orcid":false,"given":"Ola","family":"Bratt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Egevad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.02.002_b0005","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/jamaoncol.2025.4125","article-title":"Active monitoring, surgery, and radiotherapy for cribriform-positive and cribriform-negative prostate cancer: a secondary analysis of the PROTECT randomized clinical trial","volume":"11","author":"Sushentsev","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2026.02.002_b0010","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/modpathol.2016.49","article-title":"Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy","volume":"29","author":"Kweldam","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.eururo.2026.02.002_b0015","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2019.07.051","article-title":"Improved prostate cancer biopsy grading by incorporation of invasive cribriform and intraductal carcinoma in the 2014 grade groups","volume":"77","author":"van Leenders","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.02.002_b0020","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41391-024-00910-3","article-title":"Undetected cribriform and intraductal prostate cancer at biopsy is associated with adverse outcomes","volume":"28","author":"Bernardino","year":"2025","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.eururo.2026.02.002_b0025","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/his.14867","article-title":"Interobserver reproducibility of cribriform cancer in prostate needle biopsies and validation of International Society of Urological Pathology criteria","volume":"82","author":"Egevad","year":"2023","journal-title":"Histopathology"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826019925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826019925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:34:15Z","timestamp":1779917655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826019925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0302283826019925"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.02.002","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re: Active Monitoring, Surgery, and Radiotherapy for Cribriform-positive and Cribriform-negative Prostate Cancer: A Secondary Analysis of the PROTECT Randomized Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}